Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don't they seem to be handled as one?
So, is today the day?
To all, I have a question. What do you think of the future of anatabine? Will it become a huge business overall eventually, or not? What do you think?
Yes, practically worthless. So, it's easy to hold on. Haha.
You da man, bono, it seems only you and me are holding onto this great stock.
So, basically, they are lying, IMHO.
It is strange that seek_the_light posted that the lab test of HydraPharm ABloc showed that it contained anatabine citrate. My response to that post was that HydraPharm must be making it following the method of RCPI patent. Now they changed their words. HydraPharm must be monitoring this board. Who told them about this board?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137665159
I sent some of the new Anatabloc to someone who had it tested and it does contain Anatabine Citrate
Good find. It says it is pure anatabine not anatabine citrate, which means they are not infringing any RCPI patent. They must be making it in different method. But, I don't understand how they could claim it is 115% more potent than citrate salt. I doube they did any experiment.
https://www.predatornutrition.com/nootropic-supplements/hydrapharm/anatabloc.html
Pure Anatabine 115% more potent than Anatabine Citrate
Are you taking it? Is it good?
Can you notice you are getting physically younger, too? Like AnataBloc it is anti aging pill.
Any of you tried Niagen? How effective is it? It has been PCox favorite for quite a while.
I am trying two things to beat them. (Who do I mean by them?) A lot of research has been done by others and I need to do more literature search. Research results are sometimes contradicting among themselves because the result reflects the viewpoint of the sponsor, especially in tobacco related research. I don't know where this will lead, but, let's see.
Containing anatabine citrate HydraP's ABloc must have been synthesized by the method of RCPI's patent, I think.
I have consumed the last AB left a few days ago. I had 14 lozenges left with me which was bought in 2013.
I had been sparingly using it only in emergency situation like severe seasonal allergy. Back in 2013 it was so effective against my 8 year old right shoulder pain and seasonal allergy and that's why I invested in RCPI.
In the past few years I was suffering from left shoulder pain probably from two-handed backhand while playing tennis. Several days ago the pain was so severe and suddenly AB came to my mind. So, I tried 2 lozenges each at 12 hours interval for 3 times. So total 6 lozenges and that was enough to take care of the few years old left shoulder pain!!!
Now there were 8 lozenges left. That time I learned that my sister had been suffering from right shoulder pain for a few years. She never told me before. So, I gave them to her and she took them 4 times at 12 hours interval. It did not do much good for her. I think she might have needed longer treatment, who knows.
I think I have to turn to HP AB, or make anatabine myself.
I mean if it is synthesized in the same way as Rock Creek patent or in a different synthesis method.
Are you guys still taking HydraPharm ABloc? Satisfied with its efficacy? I just wonder if it is synthesized in the same way or in a different way.
I generally agree with you, but on a second thought I think Archer can simply make a license contract with PMI. Same for HydraPharm.
This could be a competition to Anatabloc. AB could be a cheaper competition to J147, though.
https://www.sciencedaily.com/releases/2018/01/180109090917.htm
Alzheimer’s drug turns back clock in powerhouse of cell
Researchers identify molecular target of J147, which is nearing clinical trials to treat Alzheimer’s disease
Date: January 9, 2018
Source: Salk Institute for Biological Studies
Summary:
The experimental drug J147 is something of a modern elixir of life; it's been shown to treat Alzheimer's disease and reverse aging in mice and is almost ready for clinical trials in humans. Now scientists have solved the puzzle of what, exactly, J147 does. They report that the drug binds to a protein found in mitochondria, the energy-generating powerhouses of cells. In turn, they showed, it makes aging cells, mice and flies appear more youthful.
Share:
FULL STORY
The experimental drug J147 is something of a modern elixir of life.
Credit: Salk Institute
The experimental drug J147 is something of a modern elixir of life; it's been shown to treat Alzheimer's disease and reverse aging in mice and is almost ready for clinical trials in humans. Now, Salk scientists have solved the puzzle of what, exactly, J147 does. In a paper published January 7, 2018, in the journal Aging Cell, they report that the drug binds to a protein found in mitochondria, the energy-generating powerhouses of cells. In turn, they showed, it makes aging cells, mice and flies appear more youthful.
"This really glues together everything we know about J147 in terms of the link between aging and Alzheimer's," says Dave Schubert, head of Salk's Cellular Neurobiology Laboratory and the senior author on the new paper. "Finding the target of J147 was also absolutely critical in terms of moving forward with clinical trials."
Schubert's group developed J147 in 2011, after screening for compounds from plants with an ability to reverse the cellular and molecular signs of aging in the brain. J147 is a modified version of a molecule found in the curry spice curcumin. In the years since, the researchers have shown that the compound reverses memory deficits, potentiates the production of new brain cells, and slows or reverses Alzheimer's progression in mice. However, they didn't know how J147 worked at the molecular level.
In the new work, led by Schubert and Salk Research Associate Josh Goldberg, the team used several approaches to home in on what J147 is doing. They identified the molecular target of J147 as a mitochondrial protein called ATP synthase that helps generate ATP-the cell's energy currency-within mitochondria. They showed that by manipulating its activity, they could protect neuronal cells from multiple toxicities associated with the aging brain. Moreover, ATP synthase has already been shown to control aging in C. elegans worms and flies.
"We know that age is the single greatest contributing factor to Alzheimer's, so it is not surprising that we found a drug target that's also been implicated in aging," says Goldberg, the paper's first author.
Further experiments revealed that modulating activity of ATP synthase with J147 changes the levels of a number of other molecules-including levels of ATP itself-and leads to healthier, more stable mitochondria throughout aging and in disease.
"I was very surprised when we started doing experiments with how big of an effect we saw," says Schubert. "We can give this to old mice and it really elicits profound changes to make these mice look younger at a cellular and molecular level."
The results, the researchers say, are not only encouraging for moving the drug forward as an Alzheimer's treatment, but also suggest that J147 may be useful in other age-associated diseases as well.
"People have always thought that you need separate drugs for Alzheimer's, Parkinson's and stroke" says Schubert. "But it may be that by targeting aging we can treat or slow down many pathological conditions that are old-age-associated."
The team is already performing additional studies on the molecules that are altered by J147's effect on the mitochondrial ATP synthase-which could themselves be new drug targets. J147 has completed the FDA-required toxicology testing in animals, and funds are being sought to initiate phase 1 clinical trials in humans.
Other researchers on the study were A. Currais, M. Prior, W. Fischer, C. Chiruta, D. Daugherty, R. Dargusch and P. Maher of the Salk Institute; E. Ratliff and K. Finley of San Diego State University; P.B. Esparza-Molto and J.M. Cuezva of the Universidad Autonoma de Madrid; and M. Petrascheck of The Scripps Research Institute.
The work and the researchers involved were supported by grants from the National Institutes of Health, California Institute of Regenerative Medicine, the Nomis Foundation, the Della Thome Foundation, the Bundy Foundation, the Hewitt Foundation, the Paul F. Glenn Center for Aging Research at the Salk Institute and the Waitt Foundation.
Story Source:
Materials provided by Salk Institute for Biological Studies. Note: Content may be edited for style and length.
Journal Reference:
Joshua Goldberg et al. The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging Cell, 2018 DOI: 10.1111/acel.12715
Cite This Page:
MLA
APA
Chicago
Salk Institute for Biological Studies. "Alzheimer’s drug turns back clock in powerhouse of cell: Researchers identify molecular target of J147, which is nearing clinical trials to treat Alzheimer’s disease." ScienceDaily. ScienceDaily, 9 January 2018. <www.sciencedaily.com/releases/2018/01/180109090917.htm>.
And those idiots have gotten together at Archer to do what?
Wasn't it Jonnie Williams' idea, vaping anatabine with or without nicotine? We don't know yet if PM's vape will include anatabine. Very likely it will if PM buys anatabine patents.
Haven't the creditors gone away yet? Why are they still there? What do they benefit from making the bankruptsy a sure thing? Are they under some instruction to do so? I was hoping they would write off the debt and go away opening the way for the company to ressurect. What do they gain from bankrupting the company they put their money into? They should have written it off by the end of last year, with some back door deal or whatever if possible.
Is PM buying all the patents? Maybe, just maybe, PM is buying only tobacco related patents and leaving anatabine patents behind probably, just probably, for JW/Mullan? What I really mean is, they would never let anatabine go if I were them. Just a thought.
Why only Philip Morris, I wonder. Disappointing that anti-aging & longevity companies are not interested.
Are you saying someone's bidding at $235,000? Who?
If no motion to object is filed within a week from now, I think it will be over. I think this board will remain as it is, in case not, I suggest we can use other board to exchange any related info :
http://investorshub.advfn.com/The-Interesting-Stuff-Board-5453/
There are several different methods to synthesize anatabine that are published, no idea if they are economically feasible. But, if ABloc becomes a success story, there will be imitation and competition. I have a different idea which requires further research.
Anyway, judging from the fact that there is no revival plan coming up, it seems there is no majority shareholder.
You can go to the court hearing and when the judge asks if anyone object you can say you object, object the sale or sale price or whatever, but of course none of us can offer any alternative, so practically we cannot do that.
Anyone living nearby? Anyone (with different agenda) can say object, I think. Hope someone go there and do that.
LutherTiggs, my reasonable thinking and common sense says this board should be kept alive by IHub, but that's just my thinking. In case this board goes away, we can go to 'The Interesting Stuff Board' and let people know this company used to have an interesting stuff
CPR, actually I had the same thought.
About the question of whether there is a majority holder or not, the several shareholders that are still active on this board are tiny holders, I assume, and there are more than a few hundreds of millions of shares on float and there must be someone who owns huge number of shares, probably more than 50%. Or, he might have failed to obtain that much, who knows.
4mark and you, I think it depends on wether Jonnie owns a lot of shares or not. If he or his party doesn't own many shares, not much incentive there for him to act like we desperately wish. That's why I asked many times who the majority holder might be. I have been wishing Johnny be goode.
Anyway, the entity that BKed the company, whoever or whatever that is, should not be allowed to get away with the patents and other assets in their hands. That is my opinion.
LutherTiggs,
"If so, I would say it would be worth bringing criminal charges against all involved. (may need a non-profit watchdog to fund such an initiative)."
Shouldn't the government be the watchdog? I think I will write letters to here and there. Time for them to work for the people.
Wonder who's evaluating/assessing the value of the asset.
Is Roskamp a shareholder? I think I saw it somewhere, but not sure.
Carole12, forget RCPI???
Where are you getting these?
If they take the IP rights only, I think they know very well that it is nothing short of a crime. They might use a 3rd party, maybe even a 4th party, it's still the same. Will they dare to do that? I have been hoping for them to come out as a savior.
OK, I see. I checked only "what is claimed" part.
No way giving up?
knuts4oe, one minor correction, I think Rock Creek's anatabine synthesis patent is solely for anatabine, not including other alkaloids. RJR's "use patent" for neurodegenerative diseases, which has been expired, covers all the nicotinic alkaloids. I might be wrong, though.
I think Jonnie has not given up anatabine. No way to give up. Somehow he will get it back. It worked so well for many people, even though these are anecdotal evidences. That's my feeling.